
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
The American Journal of Managed Care
almost 26 years ago
Patient Preferences for Laboratory Test Results Notificationalmost 26 years ago
Drugs and the Elderly, Part 1: The Problems Facing Managed Care





